120 related articles for article (PubMed ID: 33993437)
1. Mapping the Memorial Anxiety Scale for Prostate Cancer to the SF-6D.
Erim DO; Bennett AV; Gaynes BN; Basak RS; Usinger D; Chen RC
Qual Life Res; 2021 Oct; 30(10):2919-2928. PubMed ID: 33993437
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.
Yang Q; Jiang LL; Li YF; Huang D
Health Qual Life Outcomes; 2023 Nov; 21(1):122. PubMed ID: 37964348
[TBL] [Abstract][Full Text] [Related]
3. Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.
Yang Q; Huang D; Jiang L; Tang Y; Zeng D
Front Endocrinol (Lausanne); 2023; 14():1160882. PubMed ID: 37664851
[TBL] [Abstract][Full Text] [Related]
4. Associations between prostate cancer-related anxiety and health-related quality of life.
Erim DO; Bennett AV; Gaynes BN; Basak RS; Usinger D; Chen RC
Cancer Med; 2020 Jun; 9(12):4467-4473. PubMed ID: 32329252
[TBL] [Abstract][Full Text] [Related]
5. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.
Wong CK; Lam CL; Wan YF; Rowen D
Value Health; 2013; 16(2):373-84. PubMed ID: 23538190
[TBL] [Abstract][Full Text] [Related]
6. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
7. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
8. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
[TBL] [Abstract][Full Text] [Related]
9. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
10. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
11. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
12. The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.
Kontodimopoulos N
Qual Life Res; 2015 Jun; 24(6):1535-44. PubMed ID: 25391489
[TBL] [Abstract][Full Text] [Related]
13. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
14. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
15. Predicting SF-6D utility scores from the neck disability index and numeric rating scales for neck and arm pain.
Carreon LY; Anderson PA; McDonough CM; Djurasovic M; Glassman SD
Spine (Phila Pa 1976); 2011 Mar; 36(6):490-4. PubMed ID: 20847713
[TBL] [Abstract][Full Text] [Related]
16. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.
Wong CK; Lam CL; Rowen D; McGhee SM; Ma KP; Law WL; Poon JT; Chan P; Kwong DL; Tsang J
Value Health; 2012 May; 15(3):495-503. PubMed ID: 22583460
[TBL] [Abstract][Full Text] [Related]
17. Use of Bayesian methods to model the SF-6D health state preference based data.
Kharroubi SA
Health Qual Life Outcomes; 2018 Dec; 16(1):234. PubMed ID: 30563528
[TBL] [Abstract][Full Text] [Related]
18. Predicting SF-6D utility scores from the Oswestry disability index and numeric rating scales for back and leg pain.
Carreon LY; Glassman SD; McDonough CM; Rampersaud R; Berven S; Shainline M
Spine (Phila Pa 1976); 2009 Sep; 34(19):2085-9. PubMed ID: 19730215
[TBL] [Abstract][Full Text] [Related]
19. The Importance of Accounting for Parameter Uncertainty in SF-6D Value Sets and Its Impact on Studies that Use the SF-6D to Measure Health Utility.
Kharroubi SA; Beyh Y; Abdul Fattah E; Young T
Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32498412
[TBL] [Abstract][Full Text] [Related]
20. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
